Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIF-1 and tumour radiosensitivity.

B J Moeller1, M W Dewhirst

  • 1Department of Radiation Oncology, Duke University Medical Center, MSRB, Research Drive, Durham, NC 27710, UK.

British Journal of Cancer
|June 1, 2006
PubMed
Summary

Hypoxia-inducible factor-1 (HIF-1) is key to tumor radiosensitivity. Blocking HIF-1 alongside radiotherapy may improve cancer treatment, but potential challenges require careful consideration for optimal outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.

Oncogene·2021
Same author

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.

Cancer chemotherapy and pharmacology·2017
Same author

Nitroprusside improves tumor perfusion during local 42°C hyperthermia.

Veterinary anaesthesia and analgesia·2017
Same author

Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells.

Oncogene·2014
Same author

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.

British journal of cancer·2012
Same author

A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

British journal of pharmacology·2011

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiation Oncology

Background:

  • Hypoxia-inducible factor-1 (HIF-1) significantly influences tumor radiosensitivity.
  • HIF-1 is a critical regulator in cellular responses to low oxygen environments.
  • Targeting HIF-1 presents a potential strategy for enhancing radiotherapy efficacy.

Purpose of the Study:

  • To explore the rationale for combining HIF-1 blockade with radiotherapy.
  • To identify potential challenges and pitfalls associated with this combined treatment approach.
  • To outline clinical scenarios where HIF-1 inhibition could optimize tumor radiosensitivity.

Main Methods:

  • Review of existing literature on HIF-1 function and radiosensitivity.
  • Analysis of preclinical and clinical data regarding HIF-1 inhibitors.
  • Discussion of theoretical benefits and risks of combined modality treatment.

Main Results:

  • HIF-1 blockade demonstrates potential to enhance tumor cell killing by radiotherapy.
  • Combining HIF-1 inhibition with radiation therapy may overcome treatment resistance.
  • Potential pitfalls include off-target effects and complex treatment scheduling.

Conclusions:

  • Combining HIF-1 blockade with radiotherapy is a promising strategy for improving tumor radiosensitization.
  • Careful patient selection and treatment planning are crucial to mitigate risks.
  • Further clinical investigation is warranted to establish optimal therapeutic protocols.

Related Experiment Videos